Ariad Pharmaceuticals PT Lowered to $24.00 (ARIA)
Stock analysts at Maxim Group dropped their price target on shares of Ariad Pharmaceuticals (NASDAQ:ARIA) from $26.00 to $24.00 in a report issued on Monday, American Banking and Market News reports. The firm currently has a “buy” rating on the stock. Maxim Group’s price objective would indicate a potential upside of 28.41% from the company’s current price.
A number of other analysts have also recently weighed in on ARIA. Analysts at Oppenheimer upgraded shares of Ariad Pharmaceuticals (NASDAQ:ARIA) from a “market perform” rating to an “outperform” rating in a research note to investors on Monday. They now have a $24.00 price target on the stock, up previously from $23.00. Separately, analysts at BMO Capital Markets downgraded shares of Ariad Pharmaceuticals (NASDAQ:ARIA) from an “outperform” rating to a “market perform” rating in a research note to investors on Monday. They now have a $21.00 price target on the stock, down previously from $37.00. Finally, analysts at Goldman Sachs Group Inc. raised their price target on shares of Ariad Pharmaceuticals (NASDAQ:ARIA) from $20.00 to $21.00 in a research note to investors on Wednesday, September 18th. Three research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $26.70.
Shares of Ariad Pharmaceuticals (NASDAQ:ARIA) traded down 2.19% during mid-day trading on Monday, hitting $18.28. 4,420,027 shares of the company’s stock traded hands. Ariad Pharmaceuticals has a 52 week low of $15.35 and a 52 week high of $25.40. The stock has a 50-day moving average of $19.4 and a 200-day moving average of $18.72. The company’s market cap is $3.384 billion.
Ariad Pharmaceuticals (NASDAQ:ARIA) last released its earnings results on Wednesday, August 7th. The company reported ($0.37) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.40) by $0.03. The company had revenue of $13.90 million for the quarter, compared to the consensus estimate of $11.11 million. During the same quarter in the prior year, the company posted ($0.31) earnings per share. The company’s quarterly revenue was up 4302.5% on a year-over-year basis. On average, analysts predict that Ariad Pharmaceuticals will post $-1.63 earnings per share for the current fiscal year.
ARIAD Pharmaceuticals, Inc (NASDAQ:ARIA) is a global oncology company focused on the discovery, development and commercialization of medicines for the cancer patients.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.